September 27, 2010 – A post-market study investigating a new treatment for peripheral artery disease of the superficial femoral artery (SFA) has completed enrollment. The VIPER study, which is looking at the performance of the Gore Viabahn endoprosthesis with a heparin bioactive surface, enrolled 120 patients.

September 27, 2010 – A premarket approval (PMA) application has been submitted for the Formula balloon-expandable stent to help treat patients suffering from renal artery stenosis. Cook Medical’s submission to the U.S. Food and Drug Administration (FDA) included data from the REFORM trial.

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in the femoropopliteal artery. Data from the ZILVER PTX trial demonstrate that paclitaxel-eluting stents had significantly better 12-month patency rates compared to traditional angioplasty with bare-metal stents for lesions in the femoropopliteal artery (above the knee).

September 24, 2010 - The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique is safe and feasible. The results of the study, which used the CorPath 200 by Corindus Vascular Robotics, were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting.

September 24, 2010 - The U.S. Food and Drug Administration (FDA) has granted conditional approval to start a trial testing a new treatment to reduce the incidence of new onset postoperative atrial fibrillation.

September 23, 2010 - Results from the second stage of a trial studying a bioresorbable vascular scaffold were announced at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.